33.69 USD
▼-1.52-4.32%
盘后 33.68 -0.03%
2026-09-15
市值
$693.79M
市盈率
—
EPS
-5.04
股息率
—
52 周区间
15.93 – 43.66
成交量
147.59K
Beta
1.96
目标价
80.43
52W 低 15.9352W 高 43.66
价格走势
公司简介
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The comp...